Considering that lapatinib is more widely administered than neratinib in the clinical treatment of ErbB2-positive breast cancer, we treated the xenograft-bearing mice with lapatinib or the combination of lapatinib and lovastatin. This evidence concerns the gene ERBB2 and breast carcinoma.